FDA peptide compounding vote: what changes for patients (and what doesn’t)

The July 2026 FDA advisory vote did not approve BPC-157, TB-500, KPV or MOTS-c, and it did not make them lawful to compound. FDA’s Pharmacy Compounding Advisory Committee (PCAC) recommended adding all four, plus Semax and Epitalon, to the list of bulk ingredients pharmacies may compound, but the committee’s job is to “provide advice and recommendations to FDA” (Federal Register, 2026). For patients nothing changes until FDA completes a rulemaking. The strongest human evidence for any of the four is one uncontrolled case series of 16 people (BPC-157); apart from two smaller BPC-157 pilots and a 2026 three-patient report combining BPC-157 and TB-500 with other drugs [Human (case series, n=12, 2 and 3)] (Poolton 2026, a systematic review; Froum 2026), the rest is animal research.

Item	Status
US FDA status	None of the four is an FDA-approved drug (USADA, BPC-157; USADA, MOTS-c). Compounded drugs are never FDA-approved (FDA)
Compounding (503A/503B)	PCAC voted 8–6 (1 abstention) for BPC-157, KPV and TB-500 and 7–5 (2 abstentions) for MOTS-c on 2026-07-23 to recommend 503A listing, as reported by legal and trade press (FDA has posted no official tally); advisory, no FDA rule yet. Withdrawn from Category 2 (FDA, updated 2026-04-22); not on the 503A list (21 CFR 216.23)
WADA 2026	BPC-157: prohibited, S0. TB-500: prohibited, S2.3 (USADA). MOTS-c: prohibited at all times, S4.4.1. KPV: not named; check Global DRO
Strongest evidence	BPC-157: Human, case series, n=16, no control group (Lee 2021). TB-500: Animal (rats). KPV: Animal (mice). MOTS-c: Animal (mice)
Human trials	BPC-157: 3 registered, none with posted results (NCT02637284, NCT07752381, NCT07803250). TB-500: none registered on the fragment. MOTS-c: none on MOTS-c itself; 1 on the analog CB4211, completed, no results posted (NCT03998514). KPV: none registered
Next regulatory step	An FDA proposed rule in the Federal Register, then public comment, then a final rule. None published as of 2026-10-02
Last checked	2026-10-18

What changed (October 2026): FDA’s own pre-meeting review of each of the seven peptides is now summarized from the briefing documents FDA posted, the vote table notes where trade reports differ, and the athlete and what-to-watch sections cover the 2027 WADA List and the next committee meeting.

What did the FDA advisory committee vote on?

On July 23–24, 2026, PCAC reviewed seven peptides nominated for the 503A bulks list, each for a specific proposed use (FDA meeting page). The 503A bulks list is the federal list of raw ingredients a state-licensed pharmacy may use to make a custom drug when the ingredient is neither part of an approved drug nor covered by a USP quality standard (FDA). FDA has posted the briefing documents but, as of 2026-10-27, no minutes or official vote tally; the counts below are as reported by legal and trade press.

Peptide	Use nominated	Reported vote
BPC-157	Ulcerative colitis	8–6, 1 abstention: for
KPV	Wound healing, inflammatory conditions	8–6, 1 abstention: for
TB-500	Wound healing	8–6, 1 abstention: for
MOTS-c	Obesity and osteoporosis	7–5, 2 abstentions, or 8–6, 1 abstention (reports differ): for
Semax	Cerebral ischemia, migraine, trigeminal neuralgia	8–5, 1 abstention: for
Epitalon	Insomnia	7–4, 1 abstention: for
Emideltide (DSIP)	Opioid withdrawal, insomnia, narcolepsy	6–7, 1 abstention: against

Semax is covered in our Selank vs Semax evidence comparison. This guide focuses on the four peptides most often asked about after the vote.

What did FDA’s own reviewers conclude?

Before the meeting, FDA staff wrote a review of each nomination, dated May 2026 and posted with the meeting materials. Each one weighed the same criteria: the substance’s chemistry, its safety, whether it works for the proposed use, and whether it has been used historically in compounding. All seven came out against listing.

Peptide	FDA staff conclusion	Human data FDA found
BPC-157	Criteria “weigh against” listing (FDA, review dated 2026-05-11)	Small uncontrolled reports; an enema study in 24 volunteers; a 2005 colitis trial (n=53) known only from an abstract, not significant
KPV	“Propose not adding” (FDA, review dated 2026-05-12)	None by any route
TB-500	“Propose not adding” (FDA, review dated 2026-05-15)	None: “no articles were found in which TB-500 was administered to humans”
MOTS-c	“Propose not adding” (FDA, review dated 2026-05-11)	No clinical study in people
Semax	Criteria “weigh against” listing (FDA, review dated 2026-05-11)	Small uncontrolled reports (migraine, n=12; trigeminal neuralgia, n=25, no reduction in pain)
Epitalon	Criteria “weigh against” listing (FDA, review dated 2026-05-12)	One spray study in 75 women measuring a melatonin marker; no sleep outcomes
Emideltide (DSIP)	Criteria “weigh against” listing (FDA, review dated 2026-05-11)	Small, mostly intravenous studies; the placebo-controlled one (n=16) found no significant difference

The committee then voted for six of the seven anyway. Its recommendation and FDA’s own review now sit side by side, and FDA decides whether to propose a rule.

What changes for patients right now?

Legally, nothing. Federal law lets a pharmacy compound from a bulk ingredient only if it has a USP or National Formulary monograph, is a component of an FDA-approved drug, or appears “on a list developed by the Secretary through regulations” (21 U.S.C. 353a). None of the four meets any of these today: the codified list in 21 CFR 216.23 does not name them (eCFR). USADA states that “currently, there is no legal basis to include BPC-157 in any compounded medication” (USADA).

Question	Before the vote	After the vote
FDA-approved?	No	No
On the 503A bulks list?	No	No; a rule is needed
FDA Category 2?	Withdrawn April 2026	Unchanged
Interim Category 1?	No; FDA stopped categorizing nominations made on or after 2025-01-07	Unchanged
WADA status	Prohibited (KPV not named)	Unchanged
Human evidence	Case series and animal studies	Unchanged

The April 2026 withdrawal from Category 2, FDA’s list of substances with “significant safety risks”, is often misread as a promotion to Category 1. FDA’s page simply moved the peptides to a section of substances “previously in category 2” that were “withdrawn by the nominators” (FDA), and FDA says it “does not intend to place bulk drug substances nominated on or after January 7, 2025, into these categories” (FDA). None of the four holds Category 1 status.

What does “advisory” mean here?

The statute requires FDA to “convene and consult an advisory committee on compounding” before issuing rules for the bulks list (21 U.S.C. 353a(c)). Consulting is not the same as deciding. The committee gives “advice and recommendations to FDA on regulatory issues” (Federal Register); FDA then chooses whether to propose a rule, and in what form.

Two features of this vote matter for anyone reading the headlines. First, the margins were narrow: one or two votes, plus abstentions. Second, the agency’s own reviewers had argued against listing every one of the seven, in the briefing documents summarized above. FDA’s published notes on these substances flag possible immunogenicity (an immune reaction against the peptide itself) and impurity problems, and for KPV and MOTS-c the agency “has not identified any human exposure data” by any route (FDA).

How long could the rulemaking take?

A change needs notice-and-comment rulemaking: a proposed rule, a public comment period, and a final rule (FDA). The only precedent is slow. FDA proposed the first 503A bulks list on December 16, 2016 (Federal Register) and published the final rule on February 19, 2019, effective March 21, 2019 (Federal Register). The list that grew out of that rule still holds only six substances. Law-firm analyses of the July meeting expect a peptide rule in 2027 or later; FDA has announced no date.

If the peptides are listed, what would compounding look like?

Listing would open one narrow door, not a shelf. A 503A pharmacy may compound only “for an identified individual patient based on the receipt of a valid prescription order” (21 U.S.C. 353a). The product would still not be an approved drug: FDA states that “compounded drugs are not FDA-approved” and that it “does not verify the safety, effectiveness or quality of compounded drugs before they are marketed” (FDA). 503A pharmacies are also not held to the manufacturing standard (CGMP) that 503B outsourcing facilities must meet, according to the same FDA page.

A listing can also carry limits. Five of the six substances on today’s list are restricted to topical use (21 CFR 216.23). Whether FDA would attach a route or use condition to any peptide is unknown until a proposed rule appears.

What does the evidence say about each peptide?

The vote was about compounding eligibility, not about whether the peptides work. Here is where the evidence stands for each of the four.

BPC-157

BPC-157 has the most human data of the four, though all of it is small. In a retrospective chart review, 14 of 16 people who received knee injections of BPC-157, alone or with thymosin beta-4, reported pain relief [Human (case series, n=16, no control group)] (Lee 2021). An intravenous pilot in two healthy adults reported no adverse effects [Human (pilot, n=2)] (Lee 2025). No published human study covers ulcerative colitis, the use the committee reviewed. See how it compares in BPC-157 vs TB-500: differences, evidence and safety.

TB-500

TB-500 is a short fragment (LKKTETQ) of the natural protein thymosin beta-4 (FDA). In a randomized study of 32 rats, TB-500 improved the Achilles tendon’s maximum load to failure and its tissue organization versus controls, and combining it with BPC-157 added nothing over either alone [Animal (rats, n=32)] (Biçer 2026). Thymosin beta-4 itself has reached larger human trials, such as a 700-person phase 3 eye-drop study (NCT03937882), but those results do not transfer to the fragment. No genuine TB-500 trial is registered: the one ClinicalTrials.gov record naming it calls itself a “fictional study” (NCT07487363). For injury use specifically, see the peptides for injury and tendon healing, ranked by evidence.

KPV

KPV is a tripeptide (a chain of three amino acids) studied for gut inflammation. In cell studies it reduced inflammatory signaling at nanomolar concentrations, and oral KPV reduced chemically induced colitis in mice [Lab and Animal] (Dalmasso 2008). No KPV study is registered on ClinicalTrials.gov, and FDA’s notes, cited above, report no human exposure data by any route.

MOTS-c

MOTS-c is a mitochondrial-derived peptide. In mice, it prevented diet-induced obesity and insulin resistance [Animal] (Lee 2015), an encouraging lead for metabolic research. No trial of MOTS-c itself is registered on ClinicalTrials.gov; the one related record tested an analog, CB4211, and was completed with no results posted (NCT03998514). It also appears in our review of the peptides Joe Rogan has discussed.

Safety: what is still unknown

The vote did not answer any open safety question. On BPC-157, FDA wrote that it “lacks sufficient information to know whether the drug would cause harm when administered to humans”, and it lists immunogenicity risk for BPC-157, TB-500 and MOTS-c (FDA). A 2026 review in Sports Medicine concluded that “rigorous human safety data are scarce, and there is potential for serious harm to patients” (Mendias 2026). Another 2026 review lists “contamination, manufacturing impurities, inaccurate dosing, pathological angiogenesis” among the risks of unregulated injectable peptides (Moiz 2026).

The vote also does not cover gray-market “research use only” products. On 2026-08-24 FDA told one such seller that its “not for human consumption” claims did not hold when its marketing showed intended human use, and noted that injectables “bypass some of the body’s key defenses against toxins and microorganisms” (FDA warning letter). Our overview Are peptides safe? What the evidence and the FDA say covers these risks in more depth.

What about athletes?

Compounding status does not affect anti-doping rules. BPC-157 is prohibited under S0, non-approved substances (USADA). TB-500 is a named example under S2.3, growth factors (USADA). MOTS-c is prohibited at all times under S4.4.1, activators of AMP-activated protein kinase (USADA). KPV is not named; USADA directs athletes to Global DRO and its drug reference line for specific substances (USADA). On the 2027 List, in force from 2027-01-01, USADA’s examples keep BPC-157 under S0 and TB-500 under S2, and S0 now names “peptides” in general: it covers peptides with no approval for human therapeutic use, a description KPV fits (USADA athlete advisory). More on how these rules differ by drug class: peptides vs steroids vs SARMs.

What to watch next

• A proposed rule in the Federal Register. This is the first legally meaningful step, and it opens public comment (FDA). Check whether it names a route or a use.
• The meeting record. Minutes and the official tally would be posted with the other materials on the FDA meeting page (FDA).
• 21 CFR 216.23. A peptide becomes eligible for 503A compounding through this list only once it appears here (eCFR).
• The next committee meeting. FDA intends to consult the committee on GHK-Cu, for non-injectable routes, before the end of February 2027 (FDA 503A categories list, updated 2026-05-14).
• Trial results. A University of Arkansas study of BPC-157 after rotator cuff repair, with a no-treatment comparison group, is scheduled to start in January 2027 (NCT07803250).